Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Mar 30:16:963-971.
doi: 10.2147/OPTH.S354738. eCollection 2022.

Performance of a Translucent Activator for LipiFlow Vectored Thermal Pulse (VTP) Treatment of Meibomian Gland Dysfunction

Jerry G Hu  1 , Vin T Dang  2 , Daniel H Chang  2 , Damien F Goldberg  3 , Cheryl McKinnon  4 , Katherine Makedonsky  4 , Michal Laron  4 , Leilei Ji  5
Affiliations
Clinical Trial

Performance of a Translucent Activator for LipiFlow Vectored Thermal Pulse (VTP) Treatment of Meibomian Gland Dysfunction

Jerry G Hu et al. Clin Ophthalmol. .

Abstract

Purpose: Investigator feedback was used to assess the clinical use of the LipiFlow® System with the new translucent Activator Clear to successfully complete LipiFlow® treatments.

Patients and methods: This was a prospective, open-label clinical investigation. A total of 88 eyes (44 subjects) were treated using the LipiFlow® System with the new Activator Clear. Subjects diagnosed with bilateral meibomian gland dysfunction (MGD) were enrolled in the study. Each investigator performed a complete LipiFlow® treatment with the translucent Activator on both eyes of each subject. Investigators completed a questionnaire assessing the clinical use of the Activator Clear on a 5-point scale (1 - very difficult or strongly disagree, 3 - neutral, 5 - very easy or strongly agree).

Results: The new translucent Activator provided successful LipiFlow® treatments in 100% of cases, with 95% confidence interval of (96%, 100%). Additionally, the investigators agreed or strongly agreed that the translucent components of the Activator Clear made it easy to access and position the activator with confidence on the subject's eye.

Conclusion: The overall investigators' impressions on usage and functionality of LipiFlow® System with the translucent Activator were very positive. The Activator Clear enables doctors with efficient and confident positioning around patient eyelids to ensure successful LipiFlow® treatment when used as indicated.

Keywords: Activator Clear; LipiFlow® vectored thermal pulsation.

PubMed Disclaimer

Conflict of interest statement

Vin T Dang reports honoraria for consulting work from Johnson & Johnson Vision, outside the submitted work. Daniel H Chang reports personal fees, non-financial support for consultant, speaker, travel support, and grant support from Johnson & Johnson Vision, outside the submitted work. Cheryl McKinnon, Katherine Makedonsky, Michal Laron and Leilei Ji are employees of Johnson & Johnson, Inc. The other authors report no conflicts of interest in this work.

References

    1. Nichols K, Foulks G, Bron A, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52:1922–1929. doi:10.1167/iovs.10-6997a - DOI - PMC - PubMed
    1. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013;7:1797–1803. doi:10.2147/OPTH.S33182 - DOI - PMC - PubMed
    1. Johnson & Johnson Vision Care, Inc. and Johnson & Johnson Surgical Vision, Inc; 2021. TearScience® LipiFlow® Thermal Pulsation System. Available from: https://www.jnjvisionpro.com/products/eye-medical-devices/lipiflow-treat....
    1. Godin M, Stinnett S, Gupta P. Outcomes of thermal pulsation treatment for dry eye syndrome in patients with Sjogren disease. Cornea. 2018;37:1155–1158. doi:10.1097/ICO.0000000000001621 - DOI - PubMed
    1. Kenrick C, Alloo S. The limitation of applying heat to the external lid surface: a case of recalcitrant meibomian gland dysfunction. Case Rep Ophthalmol. 2017;8:7–12. doi:10.1159/000455087 - DOI - PMC - PubMed